# Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

> **NCT01723306** · PHASE2 · SUSPENDED · sponsor: **Roger Williams Medical Center** · enrollment: 48 (estimated)

## Conditions studied

- Metastatic Cancers

## Interventions

- **GENETIC:** Gene Modified T Cells

## Key facts

- **NCT ID:** NCT01723306
- **Lead sponsor:** Roger Williams Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-10
- **Primary completion:** 2016-10
- **Final completion:** 2017-08
- **Target enrollment:** 48 (ESTIMATED)
- **Why stopped:** Funding
- **Last updated:** 2016-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723306, "Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01723306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*